Navigation Links
IntelliCell BioSciences Expands Management Team
Date:4/12/2012

nt pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to enter into technology licensing agreements that cover a particular international territory or country.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact:
IntelliCell BioSciences, Inc.
Rubenstein Investor Relations
Contact: Tim Clemensen
Email Contact: 

SOURCE IntelliCell BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
2. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
3. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
6. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
7. Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEO
8. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
9. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
10. Ambit Biosciences to Present at Two Upcoming Investor Conferences
11. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Burkina Faso (PRWEB) July 10, 2014 ... Faso, today have access to an additional family ... increase access to contraception at all levels of ... a lower-dose formulation of a widely used contraceptive—Pfizer’s ... system. , Burkina Faso is the first of ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
(Date:7/10/2014)... QC (PRWEB) July 10, 2014 EvoDerma ... and convenience. This rejuvenating device now comes with a second ... develops over time. , The new cup is thinner on ... design works to target rough, thin and uneven surfaces on ... firm cup for a stimulating treatment on areas such as ...
(Date:7/10/2014)...  Kainos Capital, a firm specializing in acquiring and ... has acquired the Slim-Fast brand from Unilever. Unilever will ... the transaction were not disclosed. Slim-Fast is ... markets ready-to-drink shakes, powders, bars and snacks to retail ... in the United Kingdom and ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2
... SAN FRANCISCO, March 20, 2012 /PRNewswire/ -- ... focused on the development and commercialization of first-in-class ... that the first patient has been treated in ... patients with metastatic colorectal cancer who have become ...
... GARDEN CITY, England and BOSTON, Massachusetts, March 20, 2012 ... discovery company, announces that an operating company of Shire ... global specialty biopharmaceutical company, has exercised its exclusive option ... discovered by Heptares that is currently in preclinical development. ...
... Holdings, Inc. (OTCQB: ONVO) ("Organovo") today announced the ... At the final closing, the Company raised gross proceeds ... Units, at a price of $1.00 per Unit, to ... of common stock issued and outstanding. As ...
Cached Biology Technology:Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 2Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 3Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 4Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 5Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 2Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 3Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications 2Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications 3
(Date:7/10/2014)... 3, 2014 According to the ... (Swipe And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and ... and Banking & Finance), and Geography - Global Trends ... the global Fingerprint Sensors Market is projected to cross ... of 16.8% from 2014 to 2020. Browse ...
(Date:7/10/2014)... York , July 7, 2014 ... Transparency Market Research "Electronic Access Control Systems Market Global ... - 2019," the global Electronic Access Control systems market ... is expected to grow at a CAGR of 12.6% ... of USD 31,187.8 million in 2019. Browse ...
(Date:7/10/2014)... NORTHFIELD, Ill. , July 9, 2014 /PRNewswire-USNewswire/ ... record (EHR), spurred in large part by meaningful ... way health care providers interact with laboratory information. ... well-versed in the field of clinical informatics in ... care. To address the educational needs ...
Breaking Biology News(10 mins):Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4
... Health has named researchers at Baylor College of Medicine ... and only recipients of the inaugural Quantum Grant for ... and blood vessels for the treatment of stroke. , ... Institute of Biomedical Imaging and Bioengineering (NIBIB), part of ...
... two candidate vaccines that may eventually be used together ... are published in the December 15 issue of The ... S. Graham, MD, PhD, and colleagues from the National ... the Fred Hutchinson Cancer Research Center in Seattle, and ...
... heart muscle ?even though it was grown in the ... the goal of creating replacement parts for damaged human ... just a spoonful of loose heart cells. , This ... in growing bioengineered heart muscle, or BEHM, with organized ...
Cached Biology News:First Quantum Grant to fund stem cell repair of damage from stroke 2Progress made in HIV vaccine development 2A new approach to growing heart muscle 2A new approach to growing heart muscle 3A new approach to growing heart muscle 4
Contact us for more information...
... System enables you to insert a transposable ... DNA by in vitro transposition. It uses ... into the DNA target. Target DNA may ... DNA, depending on your interests (6-8). If ...
... APAgene kits are designed to rapidly ... using our patented APA Technology. ... at an extraordinarily competitive price. All ... kit. The Locator Kit can be ...
... c-Jun N-terminal kinase (JNK) is one ... Firefly luciferase has been used as a ... function. Luciferase provides a 1000-fold increase in ... acetyltransferase (CAT) assay. Firefly luciferase catalyzes the ...
Biology Products: